Literature DB >> 3954635

Second nonocular tumors in survivors of heritable retinoblastoma.

G T Lueder, F Judisch, T W O'Gorman.   

Abstract

We reviewed the records of 50 patients with heritable retinoblastoma to study the cause of death, if deceased, or the incidence of second nonocular malignant neoplasms. The incidence of second tumors in these patients was 6% at ten years, 14% at 20 years, and 14% at 30 years. These findings are lower than previously reported results. Pinealoma was the probable cause of death in three of the five patients who died of second nonocular tumors.

Entities:  

Mesh:

Year:  1986        PMID: 3954635     DOI: 10.1001/archopht.1986.01050150072029

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  THE RETINOBLASTOMA PROTEIN: A MASTER TUMOR SUPPRESSOR ACTS AS A LINK BETWEEN CELL CYCLE AND CELL ADHESION.

Authors:  B E Engel; W D Cress; P G Santiago-Cardona
Journal:  Cell Health Cytoskelet       Date:  2014-12-18

2.  Trilateral retinoblastoma: A systematic review of 211 cases.

Authors:  Ryuya Yamanaka; Azusa Hayano; Yasuo Takashima
Journal:  Neurosurg Rev       Date:  2017-08-16       Impact factor: 3.042

3.  Second primary tumours in hereditary- and nonhereditary retinoblastoma patients treated with megavoltage external beam irradiation.

Authors:  S M Imhof; A C Moll; P Hofman; M P Mourits; J Schipper; K E Tan
Journal:  Doc Ophthalmol       Date:  1997       Impact factor: 2.379

Review 4.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.

Authors:  Ferdinandos Skoulidis; John V Heymach
Journal:  Nat Rev Cancer       Date:  2019-08-12       Impact factor: 60.716

5.  Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.

Authors:  Steven M Corsello; Rohith T Nagari; Ryan D Spangler; Jordan Rossen; Mustafa Kocak; Jordan G Bryan; Ranad Humeidi; David Peck; Xiaoyun Wu; Andrew A Tang; Vickie M Wang; Samantha A Bender; Evan Lemire; Rajiv Narayan; Philip Montgomery; Uri Ben-David; Colin W Garvie; Yejia Chen; Matthew G Rees; Nicholas J Lyons; James M McFarland; Bang T Wong; Li Wang; Nancy Dumont; Patrick J O'Hearn; Eric Stefan; John G Doench; Caitlin N Harrington; Heidi Greulich; Matthew Meyerson; Francisca Vazquez; Aravind Subramanian; Jennifer A Roth; Joshua A Bittker; Jesse S Boehm; Christopher C Mader; Aviad Tsherniak; Todd R Golub
Journal:  Nat Cancer       Date:  2020-01-20

6.  DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.

Authors:  Chao Mao; Xiaoguang Liu; Yilei Zhang; Guang Lei; Yuelong Yan; Hyemin Lee; Pranavi Koppula; Shiqi Wu; Li Zhuang; Bingliang Fang; Masha V Poyurovsky; Kellen Olszewski; Boyi Gan
Journal:  Nature       Date:  2021-05-12       Impact factor: 49.962

7.  Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population.

Authors:  F Lesueur; H Song; S Ahmed; C Luccarini; C Jordan; R Luben; D F Easton; A M Dunning; P D Pharoah; B A J Ponder
Journal:  Br J Cancer       Date:  2006-05-09       Impact factor: 7.640

8.  The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts.

Authors:  Bernadette Sosa-García; Viviana Vázquez-Rivera; Jonathan N González-Flores; Brienne E Engel; W Douglas Cress; Pedro G Santiago-Cardona
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.